(Q33696010)

28 July 2017

title

Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group (English)

1 reference

28 July 2017

0 references

1 reference

J Lipman

1

1 reference

28 July 2017

J Scribante

2

1 reference

28 July 2017

A G Gous

3

1 reference

28 July 2017

H Hon

4

1 reference

28 July 2017

S Tshukutsoane

5

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 September 1998

1 reference

Antimicrobial Agents and Chemotherapy

28 July 2017

published in

1 reference

28 July 2017

volume

42

1 reference

28 July 2017

issue

9

1 reference

28 July 2017

page(s)

2235-2239

1 reference

Changes in vancomycin pharmacokinetics in critically ill infants

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

The selection of appropriate dosages for intravenous ciprofloxacin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Bacterial resistance to fluoroquinolones: lessons to be learned

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Bacterial resistance to fluoroquinolones

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Impact of dosage schedule of antibiotics on the treatment of serious infections

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Fluoroquinolone use and fluoroquinolone resistance: is there an association?

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105792

Subtleties of antibiotic dosages--do doses and intervals make a difference in the critically ill?

30 October 2018

1 reference

12 December 2020

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis

1 reference

12 December 2020

Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses

1 reference

12 December 2020

Questioning dosing regimens of ciprofloxacin

1 reference

12 December 2020

Should quinolones be used in the treatment of bacterial infections in neutropenic patients?

1 reference

12 December 2020

Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa

1 reference

12 December 2020

The problem of sepsis. An expert report of the European Society of Intensive Care Medicine

1 reference

12 December 2020

Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily

1 reference

12 December 2020

Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.42.9.2235

0 references

PMC publication ID

105792

1 reference

28 July 2017

1 reference